BriaCell Therapeutics Cor... (BCTX)
0.38
-0.02 (-4.98%)
At close: Jan 16, 2025, 12:08 PM
undefined% (undefined)
| Bid | 0.38 |
| Market Cap | 16.89M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -0.43 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.39 |
| Volume | 279,987 |
| Avg. Volume (20D) | 1,477,178 |
| Open | 0.41 |
| Previous Close | 0.40 |
| Day's Range | 0.38 - 0.41 |
| 52-Week Range | 0.38 - 4.61 |
| Beta | undefined |
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immun...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2012
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BCTX
Website https://www.briacell.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 3826.70% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
-39.89%
BriaCell Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
1 month ago ·
Source
+1.85%
BriaCell Therapeutics shares are trading lower after the company announced intention for a public offering of common shares and warrants, terms not disclosed.
